FL-WELLVII
3.1.2023 14:01:43 CET | Business Wire | Press release
Wellvii, manufacturer of connected smart devices for health and wellbeing, today announced a partnership with Care Daily, a software technology company with AI-based Caregiver services for senior care, to bring integrated solutions for aging-in-place experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230103005097/en/
myWellvii Platform (Photo: Business Wire)
Patients are now, more than ever, extremely receptive to personal health management solutions. The consumerization and democratization of healthcare gained significant momentum prior to the pandemic and COVID-19 has further accelerated this trend. The partnership between Wellvii and Care Daily will let users take control of their wellbeing with self-monitoring and give them an enhanced view into their overall health.
“The core devices of the myWellvii Platform; the Wellvii MVS1, Wellvii Go wearable, and Wellvii Weight scale in conjunction with the Care Daily’s AI and IoT platform will enable a comprehensive solution for families to measure their health and wellness and improve their well-being.” Mark Khachaturian, PhD CEO of Wellvii.
“Care Daily has commercialized the most advanced AI Caregiver intelligence which, until today, has primarily captured data from ambient sensors in homes to learn lifestyle patterns, trends, and activities of daily living,” said David Moss, CEO of Care Daily. “Integrating Wellvii’s core devices with our AI Caregiver services unifies the lifestyle trends in the home with the biometric trends from the resident’s body, providing an unparalleled understanding of how this person is truly doing. Senior care solutions providers are excited about the opportunity to bring these differentiated services to market under their own brands.”
Both companies are in discussions with major providers to trial the combined technology in homes. Top use cases include senior care and chronic care management.
About Wellvii
Wellvii enables the delivery of healthcare at any address through its all in one comprehensive, clinically validated, connected device that measures 11 vital parameters from the finger, including an oscillometric blood pressure finger cuff. Wellvii also introduces a comprehensive wellness scoring system including the first at-home “stress test” using its proprietary fitness challenge. For more information about the myWellvii platform, click here.
1The Wellvii MVS is not a medical device and cannot be used for clinical applications in the USA. The Wellvii VitalDetect has CE Mark clearance as a Class IIa medical device in Europe. For more information on the Wellvii VitalDetect for Europe, click here. Wellvii has 60 patents issued (57 US, 2 UK, 1 EU).
Follow Wellvii on Twitter, LinkedIn, Instagram, and Facebook.
To directly contact Wellvii: info@wellvii.com.
About Care Daily
Care Daily is the only white-label home health AI and IoT SaaS that deeply personalizes the delivery of senior care through large brands. Care Daily is backed by the NIA, and the company’s award-winning AI Caregiver software intelligence is the first to achieve scientific validation for senior care assistive services in homes. Care Daily’s AI Caregiver personality and services are uniquely configurable by partners for maximum differentiation against other brands and solutions providers. The intelligence detects falls in real-time, uncovers hidden health problems, and brings families and professional caregivers together to care for seniors. Care Daily’s white-labeled solutions are utilized by some of the largest brands to quickly deploy and continually enhance personalized healthcare services for seniors in homes and communities. To learn more, visit www.CareDaily.ai or connect with us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005097/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AIM Expands Life Sciences Supply Chain Capabilities and Hires New Partner, Thomas Ebel1.6.2026 15:01:00 CEST | Press release
AIM today announced the appointment of veteran pharma supply chain expert Thomas Ebel as Partner, effective June 15. Mr. Ebel brings more than 25 years of supply chain consulting experience at leading firms including CAMELOT, McKinsey, and Accenture, and will anchor a broader initiative to expand AIM’s end-to-end supply chain capabilities. According to Richard de Bakker, Statutory Director and Founder at AIM, the firm is significantly expanding its capabilities around “end-to-end” supply chain needs. “AIM is well known as a leader in supply chain development for launch, as well as optimization of existing supply chains — supporting clients in getting their finished products to patients,” said Mr. de Bakker. “We are now adding new capabilities in supply chain diagnostics and strategy, end-to-end planning optimization, supply reliability, and working capital optimization, among others. Combined with AIM’s established supply chain expertise, this expanded offering gives clients true ‘end-
Seoul Semiconductor's World-First 'HV Opto-Semiconductor' Powers Up Global Top 4 Automakers1.6.2026 15:00:00 CEST | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890), a global opto-semiconductor technology company, announced that its world's first High Voltage (HV) opto-semiconductor technology has entered mass production with four of the world's top automotive brands across the Americas, Europe, and Asia, with plans to expand supply to 10 models by the end of the year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601232986/en/ Comparison: Conventional 3V LED vs. Seoul Semiconductor 12V 'HV Opto-Semiconductor' (Figure: Seoul Semiconductor) The technology combines micro-scaled opto-semiconductor chips capable of 12V single-chip operation — as opposed to conventional 3V LEDs — with a high-voltage (HV) driver technology. This enables a reduction of more than 10% in the number of driver-related components used in hybrid and electric vehicles, while lowering power consumption by approximately 10%, contributing to cost reduction and simplific
Oscilloquartz delivers assured timing for mission-critical harsh environments with ruggedSync™ Series OSA 55101.6.2026 14:00:00 CEST | Press release
News summary: Defense operations require resilient timing architectures that maintain synchronization in contested and GNSS-denied environments ruggedSync™ Series OSA 5510 delivers assured timing and extended holdover in a MIL-qualified platform for tactical, deployable operations Zero-trust resiliency with diversified cPNT sources, including M-Code, PRS and STL, strengthens operational continuity for defense communications, navigation and mission-critical infrastructure Oscilloquartz today launched its ruggedSync™ Series OSA 5510, a ruggedized timing and synchronization platform engineered for defense and other harsh, mission-critical environments. Designed for deployment in tactical communications networks, mobile command centers (MCCs), aviation systems and other highly demanding operational environments, the OSA 5510 combines PTP grandmaster and NTP server functionality with synchronization assurance and resilient holdover in a compact MIL-qualified platform. Multi-band GNSS suppor
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy1.6.2026 14:00:00 CEST | Press release
- FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) submission for povetacicept, an investigational engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in adults with immunoglobulin A nephropathy (IgAN). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026. If approved, povetacicept will become the first commercialized therapy in Vertex’s emerging nephrology franchise. “The Phase 3 RAINIER trial is the largest conducted in IgAN and achieved full enrollment faster than any contemporary IgAN trial, reflecting the significant unmet need in IgAN and our urgency to bring povetacicept to patients with this serious disease,” said Nia Tatsis, Ph.D., Executi
Winston Taylor Completes Historic Transatlantic Combination1.6.2026 13:01:00 CEST | Press release
Transatlantic powerhouse law firm established for the businesses, people, and markets driving capital and innovation Winston Taylor announces today that Winston & Strawn and Taylor Wessing’s U.K.-led business have officially launched as a single combined firm, creating a premier transatlantic law firm built for the needs of the businesses, people, and markets driving capital and innovation. One of the largest transatlantic firms, with more than 1,400 lawyers spanning the United States, the United Kingdom, Europe, Latin America, and the Middle East, Winston Taylor is built to meet clients’ evolving global needs for counsel. “As Winston Taylor, we are centered on a client-first approach and will be working shoulder to shoulder with our clients at the cutting edge of industry and ingenuity,” said Chairman Steve D’Amore. “With that common purpose, we are leveraging both strength and scale by integrating our teams and offices at record speed, working at pace to create a firm that is aligned
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom